Research programme: fibrosis therapeutics - Roche
Latest Information Update: 29 Oct 2014
At a glance
- Originator InterMune
- Developer Roche
- Class Small molecules
- Mechanism of Action LOXL2 protein-inhibitors; Lysophosphatidic acid receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Fibrosis
Most Recent Events
- 01 May 2014 Early research in Fibrosis in USA (unspecified route)